Centessa Pharmaceuticals
CNTA
CNTA was delisted on the 23rd of June, 2026.
125 hedge funds and large institutions have $3.11B invested in Centessa Pharmaceuticals in 2025 Q3 according to their latest regulatory filings, with 26 funds opening new positions, 31 increasing their positions, 53 reducing their positions, and 18 closing their positions.
92% more capital invested
Capital invested by funds: $1.62B → $3.11B (+$1.49B)
47% more call options, than puts
Call options by funds: $33.2M | Put options by funds: $22.6M
44% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 18
10% more funds holding in top 10
Funds holding in top 10: 10 → 11 (+1)
7% more funds holding
Funds holding: 117 → 125 (+8)
3.24% more ownership
Funds ownership: 92.48% → 95.72% (+3.2%)
42% less repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 53
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACA
Avoro Capital Advisors
New York
|
+$103M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$43.6M |
| 3 |
PA
Perceptive Advisors
New York
|
+$34.7M |
| 4 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$31.1M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
+$29M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$27M |
| 2 |
Janus Henderson Group
London,
|
-$20M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$19.6M |
| 4 |
Millennium Management
New York
|
-$13.4M |
| 5 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
-$13.1M |
CNTA Hedge Fund Activity: Q3 2025 in Review
125 of the 7,645 institutional investors tracked by Wall St. Rank reported a position in Centessa Pharmaceuticals (CNTA) for Q3 2025, worth a combined $3.11B — up 92% from $1.62B a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new CNTA positions and 18 closed out — a net gain of 8 holders — while 31 added to existing stakes and 53 trimmed.
The largest buyer was Avoro Capital Advisors, adding an estimated $103M. The largest seller was Point72 Asset Management, cutting an estimated $27M.
- 125 institutional investors held Centessa Pharmaceuticals (CNTA) as of Q3 2025, up from 117 in Q2 2025.
- Funds reported $3.11B of Centessa Pharmaceuticals stock for Q3 2025, up 92% quarter-over-quarter.
- 26 funds opened new Centessa Pharmaceuticals positions in Q3 2025 and 18 closed out, a net change of +8 holders.
- The largest Centessa Pharmaceuticals buyer in Q3 2025 was Avoro Capital Advisors, an estimated $103M added.
- The largest Centessa Pharmaceuticals seller in Q3 2025 was Point72 Asset Management, an estimated $27M sold.
Based on aggregated 13F filings for Q3 2025.